New insider activity at Amylyx Pharmaceuticals Inc ( (AMLX) ) has taken place on October 2, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Recent transactions at Amylyx Pharmaceuticals Inc. saw significant stock sales by key executives. CFO James Frates sold 10,558 shares, amounting to $154,569. Co-CEO Joshua B. Cohen sold 29,933 shares for $429,369, while Co-CEO Justin B. Klee sold 29,975 shares, totaling $430,868. CLO Gina Mazzariello sold 8,828 shares, worth $128,623, and CMO Camille Bedrosian sold 12,039 shares for $175,408.
Recent Updates on AMLX stock
Amylyx Pharmaceuticals Inc. has seen recent developments that have influenced its stock price and analyst ratings. Guggenheim analyst Seamus Fernandez raised the price target for Amylyx to $25, citing the company’s unique positioning to capitalize on the post-bariatric hypoglycemia market and its potential to become a significant player in rare metabolic disorders. Additionally, Amylyx announced a public offering of 17.5 million shares at $10 each, aiming to raise approximately $164 million to fund commercial readiness for avexitide, research and development, and general corporate purposes. Despite these positive movements, the company faces challenges such as declining revenues and operational losses, compounded by the recent halt of the ORION program for AMX0035, which adds to the uncertainty surrounding its stock.
Spark’s Take on AMLX Stock
According to Spark, TipRanks’ AI Analyst, AMLX is a Neutral.
Amylyx Pharmaceuticals’ overall stock score is primarily impacted by its financial performance challenges, including declining revenues and operational losses. While technical analysis shows positive momentum, the company’s valuation is weak due to a negative P/E ratio and lack of dividends. The recent halt of the ORION program further adds to the uncertainty, despite some positive developments in other clinical trials.
To see Spark’s full report on AMLX stock, click here.
More about Amylyx Pharmaceuticals Inc
YTD Price Performance: 258.06%
Average Trading Volume: 1,627,147
Technical Sentiment Signal: Buy
Current Market Cap: $1.49B